Berkeley N Limketkai1, Siddharth Singh2, Vipul Jairath3,4, William J Sandborn2, Parambir S Dulai2. 1. Division of Gastroenterology & Hepatology, Stanford University School of Medicine, Stanford, California. 2. Division of Gastroenterology & Hepatology, University of California, San Diego, California. 3. Division of Gastroenterology, Western University, London, Ontario, Canada. 4. Department of Epidemiology and Biostatistics, Western University, London, Ontario, Canada.
Abstract
BACKGROUND: We assessed practice patterns for monitoring mucosal inflammation after biologic initiation and the association between monitoring approaches and development of disease-related complications for Crohn's disease (CD) and ulcerative colitis (UC). METHODS: This study used a Truven Health MarketScan (2007-2016) query for CD and UC patients initiating biologic therapy. Cumulative 24-month disease-related complications (corticosteroids, change of biologic, hospitalization, surgery) in patients undergoing proactive disease monitoring with lower endoscopy, fecal calprotectin, or cross-sectional radiographic enterography (computed tomography enterography or magnetic resonance enterography) within 6 months of biologic initiation vs no early monitoring after biologic initiation were compared. Cox proportional hazard ratios (HRs with 95% confidence intervals [CIs]) adjusted for propensity score were used. RESULTS: Within the first 24 months after biologic initiation, monitoring (proactive or reactive) was performed in 56.4% of CD patients and 67.8% of UC patients, with considerable geographic variability. Early (within 6 months) proactive monitoring was endoscopy-based (87.9%), performed in 11% of CD (n = 2195/19,899) and 12.8% of UC (n = 925/7247) patients. Compared with no early monitoring, early proactive monitoring was associated with a reduction in disease-related complications for CD (adjusted HR [aHR], 0.90; 95% CI, 0.84-0.96) and UC (aHR, 0.87; 95% CI, 0.78-0.97) and predominately driven by a reduction in corticosteroid use (CD: aHR, 0.83; 95% CI, 0.77-0.90; UC: aHR, 0.77; 95% CI, 0.69-0.87). Results were consistent across multiple sensitivity analyses. CONCLUSIONS: Early proactive monitoring of mucosal inflammation in CD and UC within 6 months of biologic initiation was associated with reduction in disease-related complications over 24 months, primarily related to reduced steroid utilization. Wide variation exists in practice patterns for monitoring of mucosal inflammation after biologic initiation.
BACKGROUND: We assessed practice patterns for monitoring mucosal inflammation after biologic initiation and the association between monitoring approaches and development of disease-related complications for Crohn's disease (CD) and ulcerative colitis (UC). METHODS: This study used a Truven Health MarketScan (2007-2016) query for CD and UC patients initiating biologic therapy. Cumulative 24-month disease-related complications (corticosteroids, change of biologic, hospitalization, surgery) in patients undergoing proactive disease monitoring with lower endoscopy, fecal calprotectin, or cross-sectional radiographic enterography (computed tomography enterography or magnetic resonance enterography) within 6 months of biologic initiation vs no early monitoring after biologic initiation were compared. Cox proportional hazard ratios (HRs with 95% confidence intervals [CIs]) adjusted for propensity score were used. RESULTS: Within the first 24 months after biologic initiation, monitoring (proactive or reactive) was performed in 56.4% of CD patients and 67.8% of UC patients, with considerable geographic variability. Early (within 6 months) proactive monitoring was endoscopy-based (87.9%), performed in 11% of CD (n = 2195/19,899) and 12.8% of UC (n = 925/7247) patients. Compared with no early monitoring, early proactive monitoring was associated with a reduction in disease-related complications for CD (adjusted HR [aHR], 0.90; 95% CI, 0.84-0.96) and UC (aHR, 0.87; 95% CI, 0.78-0.97) and predominately driven by a reduction in corticosteroid use (CD: aHR, 0.83; 95% CI, 0.77-0.90; UC: aHR, 0.77; 95% CI, 0.69-0.87). Results were consistent across multiple sensitivity analyses. CONCLUSIONS: Early proactive monitoring of mucosal inflammation in CD and UC within 6 months of biologic initiation was associated with reduction in disease-related complications over 24 months, primarily related to reduced steroid utilization. Wide variation exists in practice patterns for monitoring of mucosal inflammation after biologic initiation.
Authors: Parambir S Dulai; Barrett G Levesque; Brian G Feagan; Geert D'Haens; William J Sandborn Journal: Gastrointest Endosc Date: 2015-05-21 Impact factor: 9.427
Authors: Jean-Frederic Colombel; Remo Panaccione; Peter Bossuyt; Milan Lukas; Filip Baert; Tomas Vaňásek; Ahmet Danalioglu; Gottfried Novacek; Alessandro Armuzzi; Xavier Hébuterne; Simon Travis; Silvio Danese; Walter Reinisch; William J Sandborn; Paul Rutgeerts; Daniel Hommes; Stefan Schreiber; Ezequiel Neimark; Bidan Huang; Qian Zhou; Paloma Mendez; Joel Petersson; Kori Wallace; Anne M Robinson; Roopal B Thakkar; Geert D'Haens Journal: Lancet Date: 2017-10-31 Impact factor: 79.321
Authors: L Peyrin-Biroulet; W Sandborn; B E Sands; W Reinisch; W Bemelman; R V Bryant; G D'Haens; I Dotan; M Dubinsky; B Feagan; G Fiorino; R Gearry; S Krishnareddy; P L Lakatos; E V Loftus; P Marteau; P Munkholm; T B Murdoch; I Ordás; R Panaccione; R H Riddell; J Ruel; D T Rubin; M Samaan; C A Siegel; M S Silverberg; J Stoker; S Schreiber; S Travis; G Van Assche; S Danese; J Panes; G Bouguen; S O'Donnell; B Pariente; S Winer; S Hanauer; J-F Colombel Journal: Am J Gastroenterol Date: 2015-08-25 Impact factor: 10.864
Authors: Michael D Kappelman; Sheryl L Rifas-Shiman; Ken Kleinman; Dan Ollendorf; Athos Bousvaros; Richard J Grand; Jonathan A Finkelstein Journal: Clin Gastroenterol Hepatol Date: 2007-09-29 Impact factor: 11.382
Authors: Reena Khanna; Brian Bressler; Barrett G Levesque; Guangyong Zou; Larry W Stitt; Gordon R Greenberg; Remo Panaccione; Alain Bitton; Pierre Paré; Séverine Vermeire; Geert D'Haens; Donald MacIntosh; William J Sandborn; Allan Donner; Margaret K Vandervoort; Joan C Morris; Brian G Feagan Journal: Lancet Date: 2015-09-03 Impact factor: 79.321
Authors: Laurent Peyrin-Biroulet; Walter Reinisch; Jean-Frederic Colombel; Gerassimos J Mantzaris; Asher Kornbluth; Robert Diamond; Paul Rutgeerts; Linda K Tang; Freddy J Cornillie; William J Sandborn Journal: Gut Date: 2013-08-23 Impact factor: 23.059
Authors: Jean-Frédéric Colombel; Mary E Keir; Alexis Scherl; Rui Zhao; Gert de Hertogh; William A Faubion; Timothy T Lu Journal: Gut Date: 2016-09-02 Impact factor: 23.059
Authors: Christopher Ma; Jenny Jeyarajah; Leonardo Guizzetti; Claire E Parker; Siddharth Singh; Parambir S Dulai; Geert R D'Haens; William J Sandborn; Brian G Feagan; Vipul Jairath Journal: Clin Gastroenterol Hepatol Date: 2020-12-03 Impact factor: 11.382
Authors: Christoph Kessel; Miha Lavric; Toni Weinhage; Markus Brueckner; Sytze de Roock; Jan Däbritz; Jakob Weber; Sebastiaan J Vastert; Dirk Foell Journal: Sci Rep Date: 2021-03-23 Impact factor: 4.379
Authors: Parambir S Dulai; Robert Battat; Maria Barsky; Nghia H Nguyen; Christopher Ma; Neeraj Narula; Mahmoud Mosli; Niels Vande Casteele; Brigid S Boland; Larry Prokop; M Hassan Murad; Geert D'Haens; Brian G Feagan; William J Sandborn; Vipul Jairath; Siddharth Singh Journal: Am J Gastroenterol Date: 2020-06 Impact factor: 12.045
Authors: Benjamin Click; Edward L Barnes; Benjamin L Cohen; Bruce E Sands; John S Hanson; David T Rubin; Marla C Dubinsky; Miguel Regueiro; Derek Gazis; Julie M Crawford; Millie D Long Journal: BMC Gastroenterol Date: 2022-02-19 Impact factor: 3.067